SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.150
-0.010 (-0.46%)
At close: Aug 13, 2025, 4:00 PM
2.130
-0.020 (-0.93%)
After-hours: Aug 13, 2025, 7:28 PM EDT
SAB Biotherapeutics Employees
SAB Biotherapeutics had 63 employees as of December 31, 2024. The number of employees increased by 6 or 10.53% compared to the previous year.
Employees
63
Change (1Y)
6
Growth (1Y)
10.53%
Revenue / Employee
$1,821
Profits / Employee
-$588,177
Market Cap
22.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63 | 6 | 10.53% |
| Dec 31, 2023 | 57 | 1 | 1.79% |
| Dec 31, 2022 | 56 | -83 | -59.71% |
| Dec 31, 2021 | 139 | 53 | 61.63% |
| Dec 31, 2020 | 86 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SABS News
- 6 days ago - SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - GlobeNewsWire
- 23 days ago - SAB BIO Announces Oversubscribed $175 Million Private Placement - GlobeNewsWire
- 3 months ago - SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewsWire
- 4 months ago - SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewsWire
- 6 months ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
- 7 months ago - SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - GlobeNewsWire
- 7 months ago - SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy - GlobeNewsWire